BACKGROUND: Many placebo-controlled trials have demonstrated the efficacy of individual pharmacotherapies approved for smoking cessation. However, few direct or indirect comparisons of such interventions have been conducted. We performed a meta-analysis to compare the treatment effects of 7 approved pharmacologic interventions for smoking cessation. METHODS: We searched the US Centers for Disease Control and Prevention's Tobacco Information and Prevention database as well as MEDLINE, EMBASE and the Cochrane Library for published reports of placebo-controlled, double-blind randomized controlled trials of pharmacotherapies for smoking cessation. We included studies that reported biochemically validated measures of abstinence at 6 and 12 months. We used a hierarchical Bayesian random-effects model to summarize the results for each intervention. RESULTS: We identified 70 published reports of 69 trials involving a total of 32 908 patients. Six of the 7 pharmacotherapies studied were found to be more efficacious than placebo: varenicline (odds ratio [OR] 2.41, 95% credible interval [CrI] 1.91-3.12), nicotine nasal spray (OR 2.37, 95% CrI 1.12-5.13), bupropion (OR 2.07, 95% CrI 1.73-2.55), transdermal nicotine (OR 2.07, 95% CrI 1.69-2.62), nicotine tablet (OR 2.06, 95% CrI 1.12-5.13) and nicotine gum (OR 1.71, 95% CrI 1.35-2.21). Similar results were obtained regardless of which measure of abstinence was used. Although the point estimate favoured nicotine inhaler over placebo (OR 2.17), these results were not conclusive because the credible interval included unity (95% CrI 0.95-5.43). When all 7 interventions were included in the same model, all were more efficacious than placebo. In our analysis of data from the varenicline trials that included bupropion control arms, we found that varenicline was superior to bupropion (OR 2.18, 95% CrI 1.09-4.08). INTERPRETATION: Varenicline, bupropion and the 5 nicotine replacement therapies were all more efficacious than placebo at promoting smoking abstinence at 6 and 12 months.
BACKGROUND: Many placebo-controlled trials have demonstrated the efficacy of individual pharmacotherapies approved for smoking cessation. However, few direct or indirect comparisons of such interventions have been conducted. We performed a meta-analysis to compare the treatment effects of 7 approved pharmacologic interventions for smoking cessation. METHODS: We searched the US Centers for Disease Control and Prevention's Tobacco Information and Prevention database as well as MEDLINE, EMBASE and the Cochrane Library for published reports of placebo-controlled, double-blind randomized controlled trials of pharmacotherapies for smoking cessation. We included studies that reported biochemically validated measures of abstinence at 6 and 12 months. We used a hierarchical Bayesian random-effects model to summarize the results for each intervention. RESULTS: We identified 70 published reports of 69 trials involving a total of 32 908 patients. Six of the 7 pharmacotherapies studied were found to be more efficacious than placebo: varenicline (odds ratio [OR] 2.41, 95% credible interval [CrI] 1.91-3.12), nicotine nasal spray (OR 2.37, 95% CrI 1.12-5.13), bupropion (OR 2.07, 95% CrI 1.73-2.55), transdermal nicotine (OR 2.07, 95% CrI 1.69-2.62), nicotine tablet (OR 2.06, 95% CrI 1.12-5.13) and nicotine gum (OR 1.71, 95% CrI 1.35-2.21). Similar results were obtained regardless of which measure of abstinence was used. Although the point estimate favoured nicotine inhaler over placebo (OR 2.17), these results were not conclusive because the credible interval included unity (95% CrI 0.95-5.43). When all 7 interventions were included in the same model, all were more efficacious than placebo. In our analysis of data from the varenicline trials that included bupropion control arms, we found that varenicline was superior to bupropion (OR 2.18, 95% CrI 1.09-4.08). INTERPRETATION:Varenicline, bupropion and the 5 nicotine replacement therapies were all more efficacious than placebo at promoting smoking abstinence at 6 and 12 months.
Authors: D H Gonzales; M A Nides; L H Ferry; R P Kustra; B D Jamerson; N Segall; L A Herrero; A Krishen; A Sweeney; K Buaron; A Metz Journal: Clin Pharmacol Ther Date: 2001-06 Impact factor: 6.875
Authors: A J Garvey; T Kinnunen; B L Nordstrom; C H Utman; K Doherty; B Rosner; P S Vokonas Journal: Nicotine Tob Res Date: 2000-02 Impact factor: 4.244
Authors: P Tønnesen; S Tonstad; A Hjalmarson; F Lebargy; P I Van Spiegel; A Hider; R Sweet; J Townsend Journal: J Intern Med Date: 2003-08 Impact factor: 8.989
Authors: Jasjit S Ahluwalia; Kari Jo Harris; Delwyn Catley; Kolawole S Okuyemi; Matthew S Mayo Journal: JAMA Date: 2002 Jul 24-31 Impact factor: 56.272
Authors: Sharon M Hall; Gary L Humfleet; Victor I Reus; Ricardo F Muñoz; Diane T Hartz; Roland Maude-Griffin Journal: Arch Gen Psychiatry Date: 2002-10
Authors: Bradley N Collins; E Paul Wileyto; Freda Patterson; Margaret Rukstalis; Janet Audrain-McGovern; Vyga Kaufmann; Angela Pinto; Larry Hawk; Raymond Niaura; Leonard H Epstein; Caryn Lerman Journal: Nicotine Tob Res Date: 2004-02 Impact factor: 4.244
Authors: Taneisha S Buchanan; Carla J Berg; Lisa Sanderson Cox; Niaman Nazir; Neal L Benowitz; Lisa Yu; Olivia Yturralde; Peyton Jacob; Won S Choi; Jasjit S Ahluwalia; Nicole L Nollen Journal: Nicotine Tob Res Date: 2012-02-24 Impact factor: 4.244
Authors: Qu Cui; Linda Robinson; Dawn Elston; Fiona Smaill; Jeffrey Cohen; Corinna Quan; Nancy McFarland; Lehana Thabane; Andrew McIvor; Johannes Zeidler; Marek Smieja Journal: AIDS Patient Care STDS Date: 2011-10-18 Impact factor: 5.078
Authors: Dustin C Lee; Alan J Budney; Mary F Brunette; John R Hughes; Jean-Francois Etter; Catherine Stanger Journal: Addict Behav Date: 2014-04-13 Impact factor: 3.913
Authors: Dheeraj Gupta; Ritesh Agarwal; Ashutosh Nath Aggarwal; V N Maturu; Sahajal Dhooria; K T Prasad; Inderpaul S Sehgal; Lakshmikant B Yenge; Aditya Jindal; Navneet Singh; A G Ghoshal; G C Khilnani; J K Samaria; S N Gaur; D Behera Journal: Lung India Date: 2013-07
Authors: Dinithia Sampson; Xue Y Zhu; Suresh V K Eyunni; Jagan R Etukala; Edward Ofori; Barbara Bricker; Nazarius S Lamango; Vincent Setola; Bryan L Roth; Seth Y Ablordeppey Journal: Bioorg Med Chem Date: 2014-04-20 Impact factor: 3.641